Strategic Plan - Sickle Cell Disease
Priority: Preventing and controlling complications from hemoglobinopathies.
What is the Problem?
- Sickle cell disease (SCD) is the most common hereditary blood disorder in the United States, affecting an estimated 70,000-100,000 Americans.
- In the United States, African-Americans are affected most by the disease with 1 in 500 newborns having SCD. Other affected racial and ethnic groups include Hispanics, Asians and people of Mediterranean and Middle Eastern descent.
- The cost to individuals with SCD and to the health care system is high with the Agency for Healthcare Quality and Research estimating that hospital stays for SCD patients cost an estimated $488 million in 2004.
What Do We Know?
- Overall, people with sickle cell disease have less access to comprehensive team care than people with genetic disorders such as hemophilia and cystic fibrosis.
- Because there is no widely available cure for SCD, the goal for treatment of SCD is the prevention of complications.
What Can We Do?
- Develop a national surveillance system to collect information on SCD and its complications to help determine incidence and prevalence of the disease as well as the number and extent of complications from the disease and its treatment.
- Evaluate models of health service delivery for people with SCD.
- Collaborate with professional and community-based organizations to develop campaigns and materials that will inform and educate the public while improving the evidence-based practice of providers.
Learn more about sickle cell disease.
Learn more about NCBDDD’s strategic plan and priorities.
- Centers for Disease Control and Prevention
National Center on Birth Defects and Developmental Disabilities
1600 Clifton Road
Atlanta, GA 30333
TTY: (888) 232-6348
- Contact CDC-INFO